Home News

First quarter 2019 results presentation

Operating income, growth figures, profitability and how our products have behaved

Wed, 08/05/2019 - 12:15 0 min
Download related document
No votes yet
 
Related
ROVI achieves an increase of 29% in operating income and 74% in EBITDA
ROVI achieves an increase of 29% in operating income and 74% in EBITDA
Laboratorios Farmacéuticos Rovi, SA (BME: ROVI), company Pan-European pharmaceutical company specialized and dedicated to the research...
6 min
13/05/2021
ROVI increases its fill-finish capacity for the COVID-19 Vaccine Moderna
ROVI increases its fill-finish capacity for the COVID-19 Vaccine Moderna
Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research,...
2 min
29/04/2021
ROVI participates in the manufacture of the active substance of Moderna’s COVID...
Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research,...
2 min
12/04/2021